WHODrug Link Korea provides a bridge between WHODrug Global codes and applicable local drug codes, effectively facilitating E2B(R3) compliance for ICSR submissions within the Republic of Korea.
Meet the new E2B(R3) ICSR reporting requirements for Republic of Korea with WHODrug Link Korea. From 2021, local Korean drug code identifiers are required to be submitted when reporting domestic Korean adverse drug reaction (ADR) cases. Developed in response to the Republic of Korea’s new regulations, WHODrug Link Korea effectively converts codes from WHODrug Global to local Korean codes, making the regulatory submission process easier and more efficient for WHODrug users.
WHODrug Link Korea can for example be beneficial for multinational and domestic Marketing Authorisation Holders (MAHs) performing drug coding in WHODrug Global and is developed and actively maintained by UMC.
UMC has also reached out to vendors within the WHODrug Vendor Programme and provided them with an opportunity to share their implementation plans for WHODrug Link Korea. Click here to view the list.
The first version of WHODrug Link Korea is ready to use now. Available as .csv and .txt files, the mapping tables will be updated continuously and released twice a year, in March and September, along with WHODrug Global. WHODrug Link Korea is offered as an add-on subscription to the WHODrug Global licence. Contact UMC to upgrade your existing subscription or for more information.